Press releases
Paris (France), 17 December 2009
Ipsen’s partner Roche announces that Taspoglutide
meets its primary endpoints in two further head-to-head phase III studies with insulin glargine (Lantus®) and versus placebo in patients with high body mass index (BMI)
Taspoglutide demonstrates non-inferiority HbA1c change versus insulin glargine and superiority in HbA1c change versus placebo
Taspoglutide demonstrates non-inferiority HbA1c change versus insulin glargine and superiority in HbA1c change versus placebo
Paris (France), 14 December 2009
9th Colloque Médecine et Recherche of Fondation Ipsen in the series Endocrinology: “Novel insights in adipose cell functions”
Discovery of a new type of fat cell in humans with potential impact in obesity, diabetes, stroke, kidney failure and cancer Obesity is a problem with pressing medical, public health and social implications on a global scale
Discovery of a new type of fat cell in humans with potential impact in obesity, diabetes, stroke, kidney failure and cancer Obesity is a problem with pressing medical, public health and social implications on a global scale
Paris (France), 14 December 2009
Ipsen establishes optimal biological dose for BN 83495 steroid sulphatase (STS) inhibitor in ER-positive metastatic breast cancer.
Preliminary results of on-going Ipsen-sponsored phase I in ER-positive metastatic breast cancer trial presented at the 32nd San Antonio Breast Cancer Symposium (SABCS).
Preliminary results of on-going Ipsen-sponsored phase I in ER-positive metastatic breast cancer trial presented at the 32nd San Antonio Breast Cancer Symposium (SABCS).
Paris (France), 02 December 2009
Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in head-to-head study with sitagliptin (Januvia®) and versus placebo
Taspoglutide provides potent and durable glycemic control with superiority versus Januvia®
Taspoglutide provides potent and durable glycemic control with superiority versus Januvia®
Paris (France), 30 November 2009
The 17th Jean-Louis Signoret Neuropsychology Prize of la Fondation Ipsen is awarded to Doctor Pierre Maquet for his work on the domain of “Sleep and cognition”
Paris (France), 25 November 2009
Ipsen initiates an Advanced Endometrial Cancer program with BN83495, its first-in-class steroid sulfatase (STS) inhibitor
First patient dosed in Phase II
First patient dosed in Phase II
Paris (France), 13 November 2009
Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.
Paris (France), 29 October 2009
Ipsen announces the launch of Dysport® (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia
Dysport® represents the first new botulinum toxin type A treatment option in eight years to reach the U.S. market place.
Dysport® represents the first new botulinum toxin type A treatment option in eight years to reach the U.S. market place.
Paris (France), 29 October 2009
Ipsen’s first nine months of 2009 sales and update of Group financial objectives
• Strong third quarter: drug sales up 9.4% at constant currency – Dynamic Specialty care franchise: 16.7% sales growth at constant currency • First nine months drug sales up 7.1% year-on-year at constant currency • Group financial objectives updated
• Strong third quarter: drug sales up 9.4% at constant currency – Dynamic Specialty care franchise: 16.7% sales growth at constant currency • First nine months drug sales up 7.1% year-on-year at constant currency • Group financial objectives updated
Paris (France), 29 October 2009
Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in the first phase III clinical trial
Taspoglutide weekly demonstrated significant superiority on HbA1c over twice-daily exenatide in the treatment of patients with type 2 diabetes
Taspoglutide weekly demonstrated significant superiority on HbA1c over twice-daily exenatide in the treatment of patients with type 2 diabetes
Paris (France), 20 October 2009
Ipsen grants Menarini exclusive European licence rights to Adenuric® (febuxostat), its novel treatment for chronic hyperuricaemia in gout
• Ipsen to co-promote in France • Launch expected early 2010
• Ipsen to co-promote in France • Launch expected early 2010
Lausanne (Switzerland) and Paris (France), 13 October 2009
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer.
Developed by Debiopharm Group, triptorelin embonate 6-month will be commercialised by Ipsen in Europe.
Developed by Debiopharm Group, triptorelin embonate 6-month will be commercialised by Ipsen in Europe.
Paris (France), 12 October 2009
“Biology in Balance”
Third meeting in the “Exciting Biologies” series jointly organised by La Fondation Ipsen, Cell Press and the Massachusetts General Hospital
Third meeting in the “Exciting Biologies” series jointly organised by La Fondation Ipsen, Cell Press and the Massachusetts General Hospital
Braintree (Massachusetts, United States) and Paris (France), 09 October 2009
Ipsen acquires exclusive marketing rights of BLI-800 from Braintree for colonic cleansing before colonoscopy
A new drug in the primary care gastro-enterology franchise of Ipsen
A new drug in the primary care gastro-enterology franchise of Ipsen
Paris (France) and London (United Kingdom), 08 October 2009
Ipsen and Spirogen redesign their collaboration for the development of SJG-136 (now SG2000)
Ipsen (Euronext : FR0010259150; IPN) and Spirogen Ltd. announced today that the parties have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder SJG-136 (now known as SG2000).
Ipsen (Euronext : FR0010259150; IPN) and Spirogen Ltd. announced today that the parties have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder SJG-136 (now known as SG2000).
Paris (France), 22 September 2009
Appointment of Claude Bertand as Executive Vice President, Chief Scientific Officer of Ipsen. Jacques-Pierre Moreau is appointed Chief Scientific Advisor
to the Executive Committee.
Ipsen (Euronext: FR0010259150; IPN) today announced that Claude Bertrand will join Ipsen, as of November 2nd, as Executive Vice President, Chief Scientific Officer and Member of the Executive Committee of the Group.
Ipsen (Euronext: FR0010259150; IPN) today announced that Claude Bertrand will join Ipsen, as of November 2nd, as Executive Vice President, Chief Scientific Officer and Member of the Executive Committee of the Group.
Lausanne (Switzerland) and Paris (France), 21 September 2009
AZZALURE® approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
• This market authorisation is part of a process including 15 countries in Europe • Azzalure® will be commercialised in Spain by Galderma
• This market authorisation is part of a process including 15 countries in Europe • Azzalure® will be commercialised in Spain by Galderma
Paris (France), 15 September 2009
Encouraging preliminary new data available for the treatment of short stature children with low IGF-1 levels.
Preliminary results from a phase II study of a co-administration of rhGH/rhIGF-1 therapy and other studies presented at a major pediatric endocrinology congress (8th Joint LWPES/ESPE Meeting, New York, USA).
Preliminary results from a phase II study of a co-administration of rhGH/rhIGF-1 therapy and other studies presented at a major pediatric endocrinology congress (8th Joint LWPES/ESPE Meeting, New York, USA).
Paris (France) and Lausanne (Switzerland), 07 September 2009
Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC-25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent. Debio 0931 has the potential to target major human cancers.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Paris (France), 28 August 2009
Ipsen’s half year 2009 results
Drug sales in line with full year objective of 7.0% to 9.0% growth: • First half 2009 drug sales up 6.3% year-on-year at constant currency • Dynamic Specialty care franchise: 11.5% sales growth at constant currency. Sustained profitability: • First semester impacted by the full consolidation of US acquisitions • Group operating income1 reaches 25.0% of sales. Strong cash flow generation: • €147 million generated from operating activities during the first half 2009 • €119 million positive net cash position as of June 30, 2009.
Drug sales in line with full year objective of 7.0% to 9.0% growth: • First half 2009 drug sales up 6.3% year-on-year at constant currency • Dynamic Specialty care franchise: 11.5% sales growth at constant currency. Sustained profitability: • First semester impacted by the full consolidation of US acquisitions • Group operating income1 reaches 25.0% of sales. Strong cash flow generation: • €147 million generated from operating activities during the first half 2009 • €119 million positive net cash position as of June 30, 2009.
Paris (France), 16 July 2009
Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen’s BIM23A760 first-in-class “chimeric” compound on growth hormone, IGF-1 and prolactin levels
Ipsen (Euronext: FR0010259150; IPN) today announced the results of phase I and Phase IIa clinical studies for its BIM23A760 designed and developed by Ipsen’s research team using its validated peptide engineering platform.
Ipsen (Euronext: FR0010259150; IPN) today announced the results of phase I and Phase IIa clinical studies for its BIM23A760 designed and developed by Ipsen’s research team using its validated peptide engineering platform.
Paris (France), 10 July 2009
14th Longevity Prize of La Fondation Ipsen
Doctor Jacques Vallin is awarded for cross-national comparison of longevity through health transition
Doctor Jacques Vallin is awarded for cross-national comparison of longevity through health transition
Paris (France) and Lausanne (Switzerland), 26 June 2009
Azzalure approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
This market authorisation is part of a process including 15 countries in Europe. Azzalure® will be commercialised in Germany by Galderma.
This market authorisation is part of a process including 15 countries in Europe. Azzalure® will be commercialised in Germany by Galderma.
Paris (France), 15 June 2009
Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement
The agreement concerns innovative drug candidates issued from the Pleotherapy™ technology intended for the treatment of Charcot-Marie-Tooth disease
The agreement concerns innovative drug candidates issued from the Pleotherapy™ technology intended for the treatment of Charcot-Marie-Tooth disease
Paris (France), 10 June 2009
20th Neuronal Plasticity Prize awarded to three eminent scientists for their research into the domain of the brain-machine interaction: Alim-Louis Benabid, Apostolos P. Georgopoulos and Miguel A. L. Nicolelis
The 20th annual Neuronal Plasticity Prize has been awarded to Alim-Louis Benabid (CEA Minatec LETI,Grenoble, France), Apostolos P. Georgopoulos (University of Minnesota, Minneapolis, USA) and Miguel A. L. Nicolelis (Duke University, Durham, USA) for their research in the domain of the brain-machine interaction.
The 20th annual Neuronal Plasticity Prize has been awarded to Alim-Louis Benabid (CEA Minatec LETI,Grenoble, France), Apostolos P. Georgopoulos (University of Minnesota, Minneapolis, USA) and Miguel A. L. Nicolelis (Duke University, Durham, USA) for their research in the domain of the brain-machine interaction.
Paris (France), 04 June 2009
Ipsen’s Annual Shareholders’ Meeting on June 4, 2009
Adoption of all resolutions submitted to the Shareholders’ vote
Adoption of all resolutions submitted to the Shareholders’ vote
Paris (France), 20 May 2009
Combined General Meeting on June 4, 2009 - Availability of preliminary documents
The company’s shareholders are invited to take part in the combined General Meeting to be held on: June 4, 2009 at 9.30 a.m. at the registered office of the Company – 65, quai Georges Gorse - 92100 Boulogne-Billancourt
The company’s shareholders are invited to take part in the combined General Meeting to be held on: June 4, 2009 at 9.30 a.m. at the registered office of the Company – 65, quai Georges Gorse - 92100 Boulogne-Billancourt
Paris (France), 19 May 2009
Disclosure of trading in own shares
Ipsen (Euronext: IPN) declares below the transactions made on its own shares for the period from May 14th ,2009 until May 15th, 2009
Ipsen (Euronext: IPN) declares below the transactions made on its own shares for the period from May 14th ,2009 until May 15th, 2009
Paris (France), 14 May 2009
Disclosure of trading in own shares
Ipsen (Euronext: IPN) declares below the transactions made on its own shares for the period from 6 May 2009 until 13 May 2009.
Ipsen (Euronext: IPN) declares below the transactions made on its own shares for the period from 6 May 2009 until 13 May 2009.
Paris (France), 11 May 2009
Appointment of Jean-Christophe Tellier as President and General manager of Ipsen in North America
Jean-Christophe Tellier has joined the Ipsen Group (Euronext: FR0010259150; IPN) as President and General manager of Ipsen’s North American operations, effective 1st May 2009. He will report to Christophe Jean, Executive Vice-President, Chief Operating Officer.
Jean-Christophe Tellier has joined the Ipsen Group (Euronext: FR0010259150; IPN) as President and General manager of Ipsen’s North American operations, effective 1st May 2009. He will report to Christophe Jean, Executive Vice-President, Chief Operating Officer.
Scottsdale (Arizona, USA) and Paris (France), 30 April 2009
FDA approves Dysport(TM) for therapeutic and aesthetic uses
Ipsen's abobotulinumtoxinA approved simultaneously for the treatment of both cervical dystonia and glabellar lines under a single trade name, Dysport(TM)
Ipsen's abobotulinumtoxinA approved simultaneously for the treatment of both cervical dystonia and glabellar lines under a single trade name, Dysport(TM)
Paris (France), 28 April 2009
Ipsen’s first quarter 2009 sales and financial outlook for the full year
Ipsen (Euronext: IPN) reported today its sales for the first quarter 2009.
Ipsen (Euronext: IPN) reported today its sales for the first quarter 2009.
Paris (France), 23 April 2009
Colloque Médecine et Recherche of La Fondation Ipsen in the Neurosciences series: “Macro-roles for microRNAs in the Life and Death of Neurons”
The 17th Colloque Médecine et Recherche of La Fondation Ipsen dedicated to the Neurosciences series was held in Paris on 20 April 2009 and was titled “Macro-roles for microRNAs in the Life and Death of Neurons“.
The 17th Colloque Médecine et Recherche of La Fondation Ipsen dedicated to the Neurosciences series was held in Paris on 20 April 2009 and was titled “Macro-roles for microRNAs in the Life and Death of Neurons“.
Paris (France) and Scottsdale (Arizona, USA), 14 April 2009
Update on Ipsen's botulinum toxin type A product regulatory review status in the US
Ipsen (Euronext: IPN) and its partner Medicis (NYSE: MRX) announced today that the companies are in active labeling and Risk Evaluation and Mitigation Strategy ("REMS") discussions with the U.S. Food and Drug Administration (“FDA”) related to the Biologics License Application (“BLA”) for Ipsen’s botulinum toxin type A product in both therapeutic and aesthetic indications.
Ipsen (Euronext: IPN) and its partner Medicis (NYSE: MRX) announced today that the companies are in active labeling and Risk Evaluation and Mitigation Strategy ("REMS") discussions with the U.S. Food and Drug Administration (“FDA”) related to the Biologics License Application (“BLA”) for Ipsen’s botulinum toxin type A product in both therapeutic and aesthetic indications.
Paris (France), 08 April 2009
Colloque Médecine et Recherche of La Fondation Ipsen: “Diabetes, Insulin and Alzheimer’s Disease”
The 24th Colloque Médecine et Recherche of La Fondation Ipsen dedicated to the Alzheimer series which was hold in Paris on April 6, 2009 and entitled “Diabetes, Insulin and Alzheimer’s Disease”.
The 24th Colloque Médecine et Recherche of La Fondation Ipsen dedicated to the Alzheimer series which was hold in Paris on April 6, 2009 and entitled “Diabetes, Insulin and Alzheimer’s Disease”.
Lausanne (Switzerland) and Paris (France), 31 March 2009
AZZALURE® is approved in France for Aesthetic Use in the Treatment of Frown Lines
Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an innovation-driven international specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin Type A manufactured by Ipsen), a muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in France from the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS).
Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an innovation-driven international specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin Type A manufactured by Ipsen), a muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in France from the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS).
Paris (France), 26 March 2009
5th Colloque Médecine et Recherche of the Cancer series: “Molecular Targets of Cancer Therapy”
The 5th Colloque Médecine et Recherche in the series Cancer Science of La Fondation Ipsen, took place from February 14th to 18th this year in Jaipur (India) on the theme “Molecular Targets of Cancer Therapy”.
The 5th Colloque Médecine et Recherche in the series Cancer Science of La Fondation Ipsen, took place from February 14th to 18th this year in Jaipur (India) on the theme “Molecular Targets of Cancer Therapy”.
Lausanne (Switzerland) and Paris (France), 12 March 2009
AZZALURE® approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
First market authorisation of 15 for Azzalure® in Europe • Azzalure® will be commercialised by Galderma
First market authorisation of 15 for Azzalure® in Europe • Azzalure® will be commercialised by Galderma
Paris (France), 02 March 2009
Ipsen’s full year 2008 results
The Board of Directors of Ipsen (Euronext: IPN), chaired by Jean-Luc Bélingard, met on 27 February 2009 to review the Group’s results for 2008, published today.
The Board of Directors of Ipsen (Euronext: IPN), chaired by Jean-Luc Bélingard, met on 27 February 2009 to review the Group’s results for 2008, published today.
Paris (France), 24 February 2009
Christian de la Tour is promoted Chairman of Ipsen UK and Sean McKercher, Vice-President, Corporate Business Development
Ipsen (Euronext: FR0010259150; IPN) today announced two promotions.
Ipsen (Euronext: FR0010259150; IPN) today announced two promotions.
Paris (France) and Lausanne (Switzerland), 02 February 2009
The Health Authorities of 15 European countries give a collective green light to Azzalure® for the treatment of glabellar lines, paving the way for national marketing authorizations
Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical Group, and Galderma, the leading pharmaceutical company in dermatology, today announced that Azzalure®, a muscle relaxant specifically developed for aesthetic use, has received the collective green light from 15 European countries’ Health Authorities for the granting of national marketing authorizations. The assessment was based on clinical trials involving more than 2,600 patients, which confirmed the safety and efficacy of Azzalure®.
Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical Group, and Galderma, the leading pharmaceutical company in dermatology, today announced that Azzalure®, a muscle relaxant specifically developed for aesthetic use, has received the collective green light from 15 European countries’ Health Authorities for the granting of national marketing authorizations. The assessment was based on clinical trials involving more than 2,600 patients, which confirmed the safety and efficacy of Azzalure®.
Paris (France), 29 January 2009
Ipsen’s full year 2008 sales
• Full year 2008 sales above objectives: +8.2% performance(1) sales growth • Robust growth in speciality care: +13.9% at constant exchange rates • Sustained growth in international markets: +13.9% at constant exchange rates • North American operations performance in line with expectations.
• Full year 2008 sales above objectives: +8.2% performance(1) sales growth • Robust growth in speciality care: +13.9% at constant exchange rates • Sustained growth in international markets: +13.9% at constant exchange rates • North American operations performance in line with expectations.
Paris (France), 28 January 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge® in France
Ipsen (Euronext: IPN) announced today that it has signed an agreement with Novartis for the co-promotion in France of the antihypertensive drug Exforge®. Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis® & Nisisco®, Ipsen's new agreement strengthens the commitment of its French teams to the management of cardiovascular risk factors.
Ipsen (Euronext: IPN) announced today that it has signed an agreement with Novartis for the co-promotion in France of the antihypertensive drug Exforge®. Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis® & Nisisco®, Ipsen's new agreement strengthens the commitment of its French teams to the management of cardiovascular risk factors.
Paris (France), 19 January 2009
“Creating the future: New challenges in biology and medicine”: Ipsen gathers a panel of world-renowned scientists
To mark the occasion of moving its new corporate headquarters to Boulogne-Billancourt, near Paris, Ipsen holds today an international scientific symposium dedicated to the new challenges of biomedical research.
To mark the occasion of moving its new corporate headquarters to Boulogne-Billancourt, near Paris, Ipsen holds today an international scientific symposium dedicated to the new challenges of biomedical research.
Paris (France), 08 January 2009
Ipsen provides update on R&D pipeline and business opportunities at its Investor Day
Ipsen (Euronext: IPN) will hold today its first Investor Day at its Headquarters in Boulogne Billancourt (France). The Group’s management will provide an update on the R&D pipeline as well as an overview of its specialist care franchise, notably in the US, as well as potential opportunities across disease areas and geographies.
Ipsen (Euronext: IPN) will hold today its first Investor Day at its Headquarters in Boulogne Billancourt (France). The Group’s management will provide an update on the R&D pipeline as well as an overview of its specialist care franchise, notably in the US, as well as potential opportunities across disease areas and geographies.
Paris (France), 07 January 2009
FDA’s first-cycle review of Reloxin® extended
Ipsen (Euronext: IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin® (botulinum toxin of type A) Biologics License Application (BLA) in aesthetic indications (glabellar lines) has been extended to April 13, 2009.
Ipsen (Euronext: IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin® (botulinum toxin of type A) Biologics License Application (BLA) in aesthetic indications (glabellar lines) has been extended to April 13, 2009.
Paris (France), 05 January 2009
Ipsen announces its corporate agenda for 2009
Ipsen (Euronext: FR0010259150; IPN) announces today its corporate agenda* for 2009.
Ipsen (Euronext: FR0010259150; IPN) announces today its corporate agenda* for 2009.
